Abeona Therapeutics Announces Participation in 8th Annual SVB Leerink Global Healthcare Conference

NEW YORK and CLEVELAND, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for serious diseases, today announced that João Siffert, M.D., Chief Executive Officer, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Wednesday, February 27, 2019 at 1:00 p.m. ET.

A live webcast of the fireside chat will be available on the investor section of the Abeona Therapeutics website, www.abeonatherapeutics.com, and an archived replay will be accessible for up to 30 days.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101, its gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, and ABO-102, a novel AAV9 based gene therapy for Sanfilippo syndrome type A (MPS IIIA). The Company’s portfolio of AAV9 based gene therapies also features ABO-101 for Sanfilippo syndrome type B (MPS IIIB), and ABO-201 and ABO-202 for CLN3 disease and CLN1 disease, respectively. Its preclinical assets include ABO-401, which uses the novel AIM™ AAV vector platform to address all mutations of cystic fibrosis. Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates and is the only company with Regenerative Medicine Advanced Therapy designation for two investigational therapies (EB-101 and ABO-102). For more information, visit www.abeonatherapeutics.com.

Investor Contact:
Sofia Warner
Director, Investor Relations
Abeona Therapeutics Inc.
+1 (646) 813-4710

Media Contact:
Scott Santiamo
Director, Corporate Communications
Abeona Therapeutics Inc.
+1 (718) 344-5843

Source: Abeona Therapeutics Inc.